FutureNet has been providing medical records services and technology for more than 20 years and provides visibility to cost, quality, turnaround time and other key performance indicators (KPIs) for its medical transcription, coding and billing services.
The company is already an approved medical transcription services provider for HealthTrust and is currently recognized as Best in KLAS for transcription services and software by healthcare research firm KLAS.
FutureNet Technologies Corporation provides medical transcription, coding and billing services supported by proprietary cloud-based SaaS technology.
Founded in 1996, the company's SSAE 16/SOC 2 audited Stage 2 certified EHR products are used to support their service offerings in hundreds of hospitals and other healthcare organizations nationwide.
HealthTrust serves over 1,400 acute care facilities and more than 22,600 other locations, including ambulatory surgery centers, physician practices, long-term care and alternate care sites.
Headquartered in Brentwood, Tennessee, HealthTrust is integrated with Parallon Business Solutions, LLC a provider of healthcare business and operational services, including revenue cycle management and technology solutions.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA